Acasti to participate in the h.c. wainwright 26th annual global investment conference

Princeton, n.j., sept. 05, 2024 (globe newswire) -- acasti pharma inc. (nasdaq: acst) (acasti or the company), a late-stage, biopharma company advancing gtx-104, its novel injectable formulation of nimodipine that addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage (asah), today announced that the company will participate in the h.c. wainwright 26th annual global investment conference, to be held september 9th – 11th in new york, ny.
ACST Ratings Summary
ACST Quant Ranking